RAPP Q2 2024 Earnings — Rapport Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

RAPPRapport Therapeutics, Inc. Common Stock

$1B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$208,000

Operating Income

-$21M

Net Income

-$18M

EPS (Diluted)

$-0.09

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$346M

Total Liabilities

$9M

Stockholders' Equity

$337M

Cash & Equivalents

$110M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$208,000	-$21,000	-890.5%
Operating Income	-$21M	-$7M	-213.7%
Net Income	-$18M	-$6M	-182.7%